PD-1 blockade + chemoradiation (locally advanced cervical cancer)
Adding pembrolizumab to curative chemoradiation improved survival in high-risk locally advanced cervical cancer (KEYNOTE-A18); durvalumab in a broader population did not (CALLA).
KEYNOTE-A18: 36-month OS 82.6% vs 74.8% (HR 0.67); FDA approval for FIGO III-IVA (2024). CALLA (durvalumab) was negative, possibly because it enrolled lower-risk patients and used a different drug. Cost limits use outside high-income countries.
Pages like this
not linked directly; found by shared links- IdeaHPV circulating tumour DNA to guide cervical cancer therapy
Shares KEYNOTE-A18 / ENGOT-cx11 / GOG-3047, Cervical cancer, Pembrolizumab.
- IdeaLow-cost cobalt-60 brachytherapy for cervical cancer in every regional centre
Shares Brachytherapy, Cervical cancer.
- PairingInduction chemotherapy → chemoradiation (locally advanced cervical cancer)
Shares Brachytherapy, Cervical cancer.
- InstitutionInstituto Nacional de Enfermedades Neoplásicas
Shares Brachytherapy, Cervical cancer.
- InstitutionInstitut Salah Azaïez
Shares Brachytherapy, Cervical cancer.
- InstitutionInstitut National d'Oncologie, Rabat
Shares Brachytherapy, Cervical cancer.
- InstitutionDharmais National Cancer Center
Shares Brachytherapy, Cervical cancer.
- InstitutionInstituto Nacional de Cancerología (Colombia)
Shares Brachytherapy, Cervical cancer.